
What is claimed is:


1. A compound of having the formula XI:






XI

or a stereoisomer, pharmaceutically acceptable salt, ester, or prodrug thereof, wherein


Y-X taken together, is selected from the group consisting of




,

,

, and

.

2. A compound having the formula XIII:



XIII

or a stereoisomer, pharmaceutically acceptable salt, ester, or prodrug thereof, wherein

R_4 is selected from the group consisting of

(1) H,

(2) substituted or unsubstituted C_1-C_6-alkyl,

(3) C_1-C_6-alkyl substituted with aryl,

(4) C_1-C_6-alkyl substituted with heterocyclyl, and

(5) C_1-C_6-alkyl substituted with heteroaryl;

A is H or –$CH(CH_3)OH$–;

R_1 is H or substituted or unsubstituted C_1-C_6-alkyl;

R_2 is selected from the group consisting of

(1) H,

(2) substituted or unsubstituted C_1-C_6-alkyl,

(3) substituted or unsubstituted aryl,

(4) substituted or unsubstituted heterocyclyl,

(5) substituted or unsubstituted heteroaryl,


(6) C_1-C_6-alkyl substituted with aryl,

(7) C_1-C_6-alkyl substituted with heterocyclyl,

(8) C_1-C_6-alkyl substituted with heteroaryl,

or R_1 and R_2 together with the N atom to which they are attached can form a substituted or unsubstituted heterocyclic ring, having from 3 to 10 ring atoms, wherein 1-2 ring atoms of the heterocyclic ring system are selected from N, O and S.


3. A compound having the formula XIV:




XIV


or a stereoisomer, pharmaceutically acceptable salt, ester, or prodrug thereof, wherein

D-G-Y taken together is selected from the group consisting of


, and

or





wherein

R is selected from the group consisting of $-CH_3$, $-C_2H_5$, $-CH_2OH$, $-OH$, $-OCH_3$, $-OC_2H_5$, $-OCF_3$, $-CN$, $-NO_2$, $-CO_2H$, $-CO_2CH_3$, $-CONH_2$, $-NH_2$, $-F$, $-Cl$, $-Br$, $-CF_3$, $-N(CH_3)_2$, $-NHSO_2CH_3$, and $-NHCOCH_3$;

R_4 is selected from the group consisting of

(1) H,


(2) substituted or unsubstituted C_1-C_6-alkyl,

(3) C_1-C_6-alkyl substituted with aryl,

(4) C_1-C_6-alkyl substituted with heterocyclyl, and


(5) C_1-C_6-alkyl substituted with heteroaryl.




4. A compound having the formula XV:



XV


or a stereoisomer, pharmaceutically acceptable salt, ester, or prodrug thereof, wherein D-G-Y taken together, is selected from the group consisting of




,

,

,





















,

,

,

,

,

, and


,
or

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,




, and

wherein

R is selected from the group consisting of $-CH_3$, $-C_2H_5$, $-CH_2OH$, $-OH$, $-OCH_3$, $-OC_2H_5$, $-OCF_3$, $-CN$, $-NO_2$, $-CO_2H$, $-CO_2CH_3$, $-CONH_2$, $-NH_2$, $-F$, $-Cl$, $-Br$, $-CF_3$, $-N(CH_3)_2$, $-NHSO_2CH_3$, and $-NHCOCH_3$;



5. A compound having the formula XVI:
















XVI

or a stereoisomer, pharmaceutically acceptable salt, ester, or prodrug thereof, wherein









D-G-Y taken together, is selected from the group consisting of



,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

, and

,
or

,

,

,

,

,

,

,




wherein

R is selected from the group consisting of $-CH_3$, $-C_2H_5$, $-CH_2OH$, $-OH$, $-OCH_3$, $-OC_2H_5$, $-OCF_3$, $-CN$, $-NO_2$, $-CO_2H$, $-CO_2CH_3$, $-CONH_2$, $-NH_2$, $-F$, $-Cl$, $-Br$, $-CF_3$, $-N(CH_3)_2$, $-NHSO_2CH_3$, and $-NHCOCH_3$;

R_4 is selected from the group consisting of

(1) H,


(2) substituted or unsubstituted C_1-C_6-alkyl,

(3) C_1-C_6-alkyl substituted with aryl,

(4) C_1-C_6-alkyl substituted with heterocyclyl, and


(5) C_1-C_6-alkyl substituted with heteroaryl;


6. A compound having the formula XVII:







XVII

or a stereoisomer, pharmaceutically acceptable salt, ester, or prodrug thereof, wherein D-G-Y taken together, is selected from the group consisting of



























,

,

,

,

,

, and

,

or


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,



wherein

R is selected from the group consisting of $-CH_3$, $-C_2H_5$, $-CH_2OH$, $-OH$, $-OCH_3$, $-OC_2H_5$, $-OCF_3$, $-CN$, $-NO_2$, $-CO_2H$, $-CO_2CH_3$, $-CONH_2$, $-NH_2$, $-F$, $-Cl$, $-Br$, $-CF_3$, $-N(CH_3)_2$, $-NHSO_2CH_3$, and $-NHCOCH_3$.

7. A pharmaceutical composition comprising a compound from any one of claims 1-6 and a pharmaceutically acceptable excipient.

8. A pharmaceutical composition comprising compound from any one of claims 1-6, a second agent, and a pharmaceutically acceptable excipient, wherein the second agent is an antibacterial agent, an antiendotoxin agent, or an inhaled non-antibacterial agent for the treatment of respiratory tract infection.

9. Use of a compound from any one of claims 1-6 in the manufacture of a medicament for treating a bacterial infection.

10. Use of a compound from any one of claims 1-6 in the manufacture of a medicament for treating a bacterial infection in conjunction with a second agent, wherein the second agent is an antibacterial agent, an antiendotoxin agent, or an inhaled non-antibacterial agent for the treatment of respiratory tract infection.

11. A compound from one of claims 1-6 for use in therapy.


12. A compound from one of claims 1-6 and a second agent for use in therapy.

13. A compound from one of claims 1-6 for use in the treatment of a bacterial infection.

14. A compound from one of claims 1-6 and a second agent for use in the treatment of a bacterial infection, wherein the second agent is an antibacterial agent, an antiendotoxin agent, or an inhaled non-antibacterial agent for the treatment of respiratory tract infection.

What is claimed is:

1. A compound having the formula XIII:



XIII

or a stereoisomer, pharmaceutically acceptable salt, ester, or prodrug thereof, wherein R_4 is selected from the group consisting of

(1) H,

(2) substituted or unsubstituted C_1-C_6-alkyl,

(3) C_1-C_6-alkyl substituted with aryl,

(4) C_1-C_6-alkyl substituted with heterocyclyl, and

(5) C_1-C_6-alkyl substituted with heteroaryl;

A is H or --$CH(CH_3)OH$;

R_1 is H or substituted or unsubstituted C_{1-6}-alkyl;

R_2 is selected from the group consisting of

(1) H,

(2) substituted or unsubstituted C_1-C_6-alkyl,

(3) substituted or unsubstituted aryl,

(4) substituted or unsubstituted heterocyclyl,

(5) substituted or unsubstituted heteroaryl,

(6) C_1-C_6-alkyl substituted with aryl,

(7) C_1-C_6-alkyl substituted with heterocyclyl,

(8) C_1-C_6-alkyl substituted with heteroaryl,

or R_1 and R_2 together with the N atom to which they are attached can form a substituted or unsubstituted heterocyclic ring, having from 3 to 10 ring atoms, wherein 1-2 ring atoms of the heterocyclic ring system are selected from N, O and S.

2. The compound of claim 1, wherein R_4 is H.

3. The compound of claim 1, wherein A is --$CH(CH_3)OH$.

4. The compound of claim 1, wherein R_1 is H.

5. The compound of claim 1, wherein R_1 is H and R_2 is substituted or unsubstituted heterocyclyl or C_1-C_6-alkyl substituted with heterocyclyl, wherein the heterocyclyl group is selected from the group consisting of pyridine, pyrrolidine, thienyl and piperidine.

6. The compound of claim 1, wherein R_1 and R_2 together with the N atom to which they are attached can form a substituted or unsubstituted heterocyclic ring selected from the group consisting of morpholine, piperazine, piperidine and pyrrolidine.

7. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient.

8. A pharmaceutical composition comprising the compound of claim 1, a second agent, and a pharmaceutically acceptable excipient, wherein the second agent is an antibacterial agent, an antiendotoxin agent, or an inhaled non-antibacterial agent for the treatment of respiratory tract infection.